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Progressive multifocal leukoencephalopathy (PML) is an 
opportunistic infection caused by JC virus (JCV). PML is a 
known risk associated with natalizumab (NAT, Tysabri®, 
Biogen Idec, USA), an anti-alpha-4 integrin monoclonal 
antibody approved for the treatment of severe and other-
wise treatment-resistant relapsing–remitting multiple scle-
rosis (RRMS). The overall risk of NAT-associated PML, 
estimated around 0.2%, increases with the number of infu-
sions, positive JCV antibody status, and previous treatment 
with immunosuppressive agents.1 Here we report on two 
multiple sclerosis (MS) patients who were treated in the 
same medical practice, and who were diagnosed with PML 
within four months of each other. They both belonged to an 
otherwise unrelated “infusion group” of four patients who, 
for at least four years, received their monthly infusions at 
the same times and in the same room. They had not previ-
ously been treated with an immunosuppressive agent. The 
coincidental occurrence of two PML cases in the same infu-
sion group has not been described so far. Understandably, 
the patients and their treating neurologist were concerned 
about the possibility of viral transmission.
Case reports
Patient #1, a 53-year-old male from Germany, received NAT 
for RRMS from February 2007 through February 2011 (52 
infusions). Beforehand, he had failed on beta-interferon 
therapy, but had never received immunosuppressants. NAT 
was discontinued because of the diagnosis of PML (March 
2011) with cognitive decline and personality change, typical 
magnetic resonance imaging (MRI) lesions, and high JCV 
DNA loads (1.7 × 106 Geq/ml in cerebrospinal fluid (CSF), 
2.4 × 106 Geq/ml in serum, tested in Munich, Germany). His 
neurological condition stabilized after plasmapheresis and 
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prolonged treatment with steroids without signs of immune 
reconstitution syndrome (IRIS). After six months, he had 
gradually improved but severe neuropsychological deficits 
remained (Expanded Disability Status Scale (EDSS) 5.0).
Patient #2 is a 45-year-old German woman who was 
started on NAT in November 2007 because of ongoing dis-
ease activity despite interferon therapy. She had never been 
treated with immunosuppressants. During NAT therapy she 
showed neither clinical nor MRI evidence of disease activ-
ity. After patient #1 was diagnosed with PML, and after she 
tested positive for anti-JCV-antibodies (Abs), she decided 
to stop NAT after 49 infusions in July 2011 because of fear 
of PML. Six weeks later she developed new brainstem 
symptoms and showed a progressive brainstem-midbrain 
lesion on MRI. PML was diagnosed in September 2011 
after detection of JCV DNA (31 c/ml in CSF, 5 c/ml in 
serum, Dusseldorf laboratory; EDSS 7.0). She developed 
severe IRIS, and subsequently stabilized after treatment 
with steroids and intravenous immunoglobulin.2 After six 
months, she had slightly improved but severe ataxia and 
ocular motor deficits remained (EDSS 6.0).
After PML was diagnosed in patient #1, serum JCV Abs 
were tested in all four patients of the infusion group. Three 
patients, including patients #1 and #2, were JCV Abs-
positive, one patient negative. After patient #2 was diag-
nosed with PML, the two remaining patients, including the 
JCV Abs-negative patient, decided to stop NAT because 
they were concerned about infection.
Results
JCV sequence analysis
DNA of the JCV non-coding regulatory region (NCRR) 
was amplified by PCR from the CSF of patients #1 and #2 
according to published methods.3,4 The figure shows com-
parative alignments of the JCV NCRR sequences from 
patients #1 and #2, as well as representative, hypervariable 
sequence types IIS, IS, IR and IIR (scaled linear depic-
tion).3 The NCRRs from patients #1 and #2 are unique. 
They differ from each other and from the archetype, show 
deletion of the D region, and contain repeats typical of JCV 
variants found in PML tissues. Together, these features 
strongly argue against the possibility that viral transmission 
occurred between PML patients #1 and #2.
Discussion
We investigated the possibility of viral transmission between 
members of the infusion group. It is thought that the circulat-
ing genotype or “strain” of JCV is the “archetype” that has a 
signature nucleotide sequence in its NCRR. It can multiply 
in the kidney and be excreted into the urine. It also has the 
ability to enter the bloodstream and to distribute into other tis-
sues. It is thought that in lymphoid tissues a ‘rearrangement’ 
takes place in the NCCR that might be specific to each 
patient. If a virus with an NCCR that has rearranged enters 
the brain, it can infect oligodendrocytes and initiate PML. 
The variant JCV can be detected in the CSF by PCR and is 
similar to what has been identified in the brain of the same 
patient. The observation that the NCRR regions of the 
mutated viruses of the two PML patients were different from 
each other likely excludes the possibility that the JCV vari-
ant from one patient spread to the other patient (Figure 1). 
There remains the remote possibility that an archetype-like 
strain of JCV spread by de novo infection from one patient to 
the other at an earlier time-point, and subsequently mutated 
independently in the two patients. To investigate the possi-
bility of de novo infection, we searched to obtain serum sam-
ples taken before NAT was started. We were able to locate a 
pre-treatment serum sample from each of the two patients 
who later developed PML (patient #1 and #2). Both sera 
were retrospectively found to be positive for anti-JCV anti-
bodies, speaking against the contingency of de novo infec-
tion of these patients.
The occurrence of two cases of PML among four members 
of an infusion group who had been treated together for more 
than four years at the same times in the same room of the 
same medical practice created much concern among the 
patients and treating neurologist. The probability that two 
cases of PML occur in a given infusion group is very low. 
Assuming an overall PML risk of approximately two of 1000, 
the probability of at least two cases of PML occurring in a 
given group of four is only 2.4 × 10-5. In contrast, the proba-
bility of co-occurrence of at least two PML cases taking place 
anywhere in the world is much higher, as indicated by the 
following rough estimate. Assuming that all patients are cur-
rently treated with NAT in groups of four (100,000 patients 
treated in 25,000 groups of four), and assuming an individual 
PML risk of 0.2%, the probability of at least one “PML co-
occurrence” worldwide is 45%. Based on these estimates, one 
would predict that additional PML co-occurrences will hap-
pen over time. Furthermore, we roughly estimated the prob-
ability that at least two cases of PML might occur in a large 
neurological practice. Assuming that a neurologist treats 200 
MS patients with NAT, 50% of whom are JCV negative and 
50% seropositive but without prior immunosuppressive treat-
ment, the probability of two or more PML cases among these 
patients within two to four years of therapy is 8%, based on 
the figures published by Biogen Idec in July 2012 (pJCV neg = 
0.09/1000; pJCV pos/IS neg = 4.6/1000; calculations in R using 
binomial distributions). This is a lower limit considering that 
in reality some of the patients likely were pretreated with an 
immunosuppressant agent.
Summarizing for our cases, the results of the virological 
investigations likely excluded the possibility of viral 
transmission among members of the infusion group. 
Consequently, there is presently no need to alter current 
infusion practices, which will be reassuring to patients and 
neurologists.
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Figure 1. Scaled linear depiction of JC virus (JCV) non-coding regulatory region (NCRR) sequences with comparative alignments of 
representative, hypervariable sequence types (IIS, IS, IR, and IIR3) and nucleotide sequences from Cases 1 and 2.
Modified nucleotide-numbering system adapted from the PrototypeMad-1 JCV genome.4 The NCRR is positioned between the early (dark arrow on 
left) and late (light arrow on right) protein coding sequences within the circular, supercoiled, double stranded JCV DNA genome. From the early 
side, the initial sequence section contains the origin of DNA replication (ORI) followed by sequence sections designated a, b, c, d, e and f. The base-
pair length of each sequence section is noted. From variant to variant, the dark bar, v, denotes sequence sections most likely to present deletions, 
replications and/or unique arrangements compared with Archetype or Prototype. The type IIS ArchetypeCY NCRR sequence contains a single copy 
of all NCRR sequence sections observed in other JCV variants.5 Because the v of ArchetypeCY is nine base pairs shorter than the v of PrototypeMad-1, 
the nucleotide numbering for all base pairs, excluding 1 through 36, has been modified accordingly. The ‘A’ identifies a point mutation from ‘G’ that is 
always found in type IS and IR JCV NCCR sequences.
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